RxDoctor Payments Data

David Picklesimer, MD

Family Medicine · Shelbyville, KYNPI 1285194258

Payments from drug & device makers

$1,587in general payments, 2019–2025

Across 92 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$317
  • GSK$223
  • Novo Nordisk$182
  • Johnson & Johnson$176
  • Pfizer$168
  • Boehringer Ingelheim$69
  • plus $452 from 16 others

What the payments were for

  • Food & beverage$1,57599%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,587 in reported general payments places this provider in the 65th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$32,567
Medicare patients
124
Services billed
340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide17$19,859
JanuviaSitagliptin Phosphate11$16,800
JardianceEmpagliflozin14$16,100
RybelsusSemaglutide16$14,651
XareltoRivaroxaban22$13,847
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,689
Fenofibrate12$2,531
Zolpidem Tartrate21$1,277
Icosapent Ethyl13$1,264
Metoprolol Succinate63$1,026
Propranolol Hcl12$912
ValacyclovirValacyclovir Hcl11$566
Pantoprazole Sodium46$557
Losartan Potassium38$539
Atorvastatin Calcium85$537

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$317$19,85917 claims
MerckJanuvia$33$16,80011 claims
Boehringer IngelheimJardiance$69$16,10014 claims
Novo NordiskRybelsus$182$14,65116 claims
Johnson & JohnsonXarelto$176$13,84722 claims
GSKTrelegy Ellipta$223$9,68913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Shelbyville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →